K2 Principal Fund’s Aimmune Therapeutics AIMT Stock Holding History

K2 Principal Fund’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-17,952	Closed	-$618K	–	438
2020 Q3	$618K	Buy	+17,952	New	+$382K	0.09%	185

K2 Principal Fund's AIMT Position: Q4 2020 in Review

K2 Principal Fund sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 17,952 shares — an estimated $618K sold.

K2 Principal Fund first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $618K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

K2 Principal Fund reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
K2 Principal Fund sold 17,952 Aimmune Therapeutics shares in Q4 2020, an estimated $618K.
K2 Principal Fund first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
K2 Principal Fund's Aimmune Therapeutics position peaked at $618K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on K2 Principal Fund's 13F filing for Q4 2020, filed 12 Feb 2021.